Tag: options

BEIJING, China, July 29, 2025 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today officially launched Li i8, a six-seat battery electric family SUV. As an SUV of the new era, Li i8 combines the all-terrain capabilities of off-road vehicles, the handling dynamics of sedans, and the comfort of MPVs, redefining family mobility with an all-new driving and riding experience.

MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Trawick International, a leading provider of international travel insurance and assistance services, is proud to announce a new strategic partnership with AmTrust Financial Services, Inc., a global powerhouse in specialty insurance solutions.

Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause severe side effects like osteoporosis, growth stunting, and metabolic issues.

FORM 8.3

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- With consumers increasingly searching for comfortable rings, hypoallergenic fine jewelry, and daily-wear engagement rings, She Said Yes is answering the call—introducing a new design standard that blends beauty with all-day comfort.

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses IRobot (IRBT) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Petco (WOOF) To Contact Him Directly To Discuss Their Options

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI^® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.¹